Skip to main content
Clinical Trials/EUCTR2011-000579-15-IT
EUCTR2011-000579-15-IT
Active, not recruiting
Not Applicable

Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period - Phase II exploratory study

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER0 sites36 target enrollmentMarch 19, 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
Enrollment
36
Status
Active, not recruiting
Last Updated
12 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 19, 2012
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Male or female patients aged 18 years or more \- Established diagnosis of CPVT type 1 \- Treatment with beta\-blocker \- Qualifying ETs meeting a predefined degree of severity and stability of the disease
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 36
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \- Resting ECG with an abnormality that could preclude a proper interpretation of the ECG obtained during the ETs \- Chronic heart failure \- Structural congenital heart disease

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-000579-15-GBInstitut de Recherches Internationales Servier36
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-000579-15-DEInstitut de Recherches Internationales Servier
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1
EUCTR2011-000579-15-FIInstitut de Recherches Internationales Servier
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-000579-15-HUInstitut de Recherches Internationales Servier36
Completed
Phase 2
Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period - Phase II exploratory studycatecholaminergic polymorphic ventricular tachycardiainheritated heartrhythmdisorder10007521
NL-OMON37671Servier R&D Benelux3